






**[1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES****Publication number:** EP1116722**Publication date:** 2001-07-18**Inventor:** SHIMADA JUNICHI (JP); IMMA HIRONORI (JP);  
OSAKADA NAOTO (JP); SHIOZAKI SHIZUO (JP);  
KANDA TOMOYUKI (JP); KUWANA YOSHIHISA (JP)**Applicant:** KYOWA HAKKO KOGYO KK (JP)**Classification:****- International:** A61P25/24; A61P25/28; C07D487/04; A61P25/00;  
C07D487/00; (IPC1-7): C07D487/04; A61K31/505**- European:** C07D487/04**Application number:** EP19990944771 19990922**Priority number(s):** WO1999JP05176 19990922; JP19980267178 19980922**Also published as:** WO0017201 (A1)  
 US6545000 (B1)  
 EP1116722 (A4)  
 CA2344828 (A1)  
 EP1116722 (B1)

more &gt;&gt;

**Cited documents:** EP0667349  
 EP0459702**Report a data error here.****Abstract of EP1116722**

Ä1,2,4ÜTriazoloÄ1,5-cÜpyrimidine derivatives represented by the general formula (I) <CHEM> or pharmacologically acceptable salts thereof which show adenosine A2A receptor antagonism, wherein R<1> represents heteroaryl, etc.; R<2> represents hydrogen, etc.; na and nb represent each an integer of 0 to 4; Q represents hydrogen, etc.; R<4> and R<5> represent each lower alkyl or aryl, or R<4> form together with the adjacent carbon atom a saturated carbon ring when R<3> is any of (i) to (iii); or R<4> represent each hydrogen, lower alkyl or aryl, or R<4> and R<5> form together with the adjacent carbon atom a saturated carbon ring when R<3> is (iv).

---

Data supplied from the esp@cenet database - Worldwide